There are different causes of stroke, but the most common is a blockage of blood flow to part of the brain, which is called an ischemic stroke. Transient ischemic attacks, or TIAs — sometimes also ...
The incidence of stroke continues to increase for adults and children living with sickle cell disease (SCD) despite the Stroke Prevention Trial in Sickle Cell Anemia (STOP) establishing standards of ...
ML-218 is an orally active, selective, and potent T-type calcium channel (Cav3.1, Cav3.2 and Cav3.3) inhibitor. Previous research has shown that ML-218 penetrates the blood-brain barrier and exerts ...
TBO-309 is under clinical development by AstraZeneca and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase II drugs for Acute Ischemic Stroke have a 47% phase transition ...